Search clinical trials for: BI 1595043

Total 1214 results

Boehringer Ingelheim

Completed

BI 2536 BS in Patients With Advanced Solid Tumours and Repeated Administration in Patients With Clinical Benefit

Neoplasms
Boehringer Ingelheim

Terminated

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 730357 is Processed by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of [14C]-BI 409306 After Administration as Oral Solution in Healthy Male Volunteers

Healthy

United Kingdom
Boehringer Ingelheim

Recruiting

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

Obesity

United States, Korea, Republic of, Belgium, Australia, United Kingdom, Mexico, Spain, Germany, Taiwan, Netherlands, Brazil, Hungary, Denmark, Canada, Poland, Austria, China, Finland, Greece, Italy, Hong Kong, Czechia, Portugal, Saudi... and more
Assiut University
WGEKHALEEL; AARMHUSSIEN

Recruiting

HFNC in Management of Bronchiectasis Exacerbation

Bronchiectasis

Egypt
Boehringer Ingelheim

Recruiting

A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms (VITALISScE™)

Scleroderma, Systemic

United States, Belgium, Korea, Republic of, Australia, China, Taiwan, Spain, Israel, Japan, Mexico, Turkey, Germany, Italy, Brazil, France, Singapore, India, Philippines, United Kingdom, Switzerland, Finland, Greece, New Zealand, Denmark and more
Boehringer Ingelheim

Recruiting

A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma

Glioblastoma

Belgium, Spain, United States
Universitat Jaume I

Not yet recruiting

Blended Treatment for Problem Gambling and Gambling Disorder Combining Group Sessions and Online Modules

Gambling Disorder | Problem Gambling

Spain
Boehringer Ingelheim

Completed

A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight

Obesity

Belgium, Australia, Sweden, United States, Canada, Germany, Korea, Republic of, China, Netherlands, New Zealand, United Kingdom, Poland
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 456906 is Processed in the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients

Multiple Myeloma

Germany, France
Boehringer Ingelheim

Completed

Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks

Migraine Disorders

Belgium, Germany
Stereotaxis

Terminated

MAGNET CRT Feasibility - Efficiency of LV Lead Placement Comparing Conventional vs. Magnetic Guidance

Cardiac Resynchronization Therapy

United States
AbbVie

No longer available

Expanded Access to Risankizumab

Crohn's Disease | Ulcerative Colitis (UC)
University of Reading
Danisco

Completed

A Study of a Prebiotic, a Probiotic and a Synbiotic Upon the Gut Microbiota and Immune Response of Healthy Volunteers (XOS)

Gut Microbiota | Immune Function | Bowel Function | Plasma Lipids

United Kingdom
William Beaumont Hospitals
Haines, David MD

Completed

Biventricular Pacing In Patients With Left Ventricular Dysfunction After Cardiovascular Surgery

Thoracic Surgery | Heart Failure, Congestive | Cardiomyopathy

United States
Boehringer Ingelheim

Completed

Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial

Hepatitis C

Japan
Boehringer Ingelheim

Completed

To Investigate the Safety, Tolerability, Pharmacokinetics and the Relative Bioavailability of BI 1026706

Healthy

Germany
Boehringer Ingelheim

Completed

4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
Boehringer Ingelheim

Completed

Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)

Hepatitis C, Chronic

United States, Argentina, Australia, Austria, Canada, Czech Republic, France, Germany, Korea, Republic of, Netherlands, Portugal, Romania, Spain, Switzerland, United Kingdom
Boehringer Ingelheim

Completed

Bioavailability of Soft Gelatin Capsule Formulation of BI 201335 NA Compared to the Solution Formulation in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1

Hepatitis C, Chronic

United States, Austria, Canada, France, Germany, Hungary, Ireland, Italy, Netherlands, Portugal, Romania, Russian Federation, Spain, United Kingdom
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 207127 NA in Healthy Male Asian Volunteers and Single Dose Study of BI 207127 NA in Healthy Male Caucasian Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Active, not recruiting

A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

Head and Neck Squamous Cell Carcinoma (HNSCC)

Spain, United States, United Kingdom, France, Thailand, Malaysia, Mexico, Romania, Poland, Japan, Moldova, Republic of
Boehringer Ingelheim

Terminated

A Study in Healthy Men to Test How BI 1265162 is Taken up and Processed by the Body

Healthy Volunteers

Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How the Body Takes up and Tolerates Different Doses of BI 474121, and Whether it Makes a Difference if BI 474121 is Taken as a Tablet or a Drink.

Healthy

Germany
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of Oral Solution of [14C]-BI 201335 in Healthy Male Volunteers

Healthy
Boehringer Ingelheim
Eli Lilly and Company

Completed

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Croatia, Czech Republic, Denmark, Estonia, France, Georgia, Greece, Hong Kong, Hungary, India, Indonesia, Israel, Italy, Japan, Korea, Republic of, Malaysia and more
Rhode Island Hospital
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Recruiting

Intervention to Prevent Peer Violence & Depressive Symptoms Among At-Risk Adolescents (iDOVE2)

Depressive Disorder | Violence

United States
Boehringer Ingelheim

Terminated

Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States, Germany
Boehringer Ingelheim

Completed

Effect of Food on the Pharmacokinetics of BI 1060469 (Formulation Tablet) in Healthy Male Subjects

Healthy

Germany
Organogenesis

Terminated

Apligraf Versus Standard Therapy in the Treatment of Diabetic Foot Ulcers

Diabetic Foot
The University of Tennessee, Knoxville

Completed

In Vivo Kinematics for Subjects With Smith & Nephew Journey II BCS TKA, Journey II CR TKA, Or Journey II XR TKA

Knee Osteoarthritis | Total Knee Arthroplasty | Knee

United States
Boehringer Ingelheim

Completed

Single Rising Oral Doses of BI 207127 NA as Powder in the Bottle in Healthy Male Subjects

Healthy
Shenzhen Geno-Immune Medical Institute

Recruiting

GD2/CD70 Bi-specific CAR-T Cell Therapy

Cancer Disease

China
Shenzhen Geno-Immune Medical Institute

Recruiting

GD2/PSMA Bi-specific CAR-T Cell Therapy

Solid Tumor

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/22 Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
AbbVie

Completed

A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) (LIMMITLESS)

Psoriasis

United States, Australia, Austria, Belgium, Canada, Czechia, Finland, France, Germany, Japan, Korea, Republic of, Mexico, Poland, Portugal, Spain, Sweden, Taiwan
Boehringer Ingelheim

Completed

A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread

Neoplasms

United States
Julieta Azevedo
Fundação para a Ciência e a Tecnologia; Centro Hospitalar e Universitário de... and other collaborators

Completed

Bi-REAL - DBT Skills Online Group Intervention for Bipolar Disorder (BI-REAL)

Bipolar Disorder

Portugal
AbbVie

Completed

A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

Dermatitis

United States, Australia, Canada, Japan, Puerto Rico
Boehringer Ingelheim

Terminated

This Study Tests How Different Doses of BI 1291583 Are Taken up in the Body and How Well They Are Tolerated

Healthy

Germany
Fondazione del Piemonte per l'Oncologia

Completed

Comparison of Multi-parametric and Bi-parametric Magnetic Resonance Imaging in Men With Suspicion of Prostate Cancer

Prostatic Neoplasm

Italy
AbbVie

Completed

A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)

Psoriatic Arthritis
Boehringer Ingelheim

Completed

Influence of a Standardised High Fat Breakfast on the Bioavailability of BI 14332 CL in Healthy Male Volunteers

Healthy
BioInvent International AB

Completed

A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma

Multiple Myeloma

Denmark, Belgium, United States, Sweden
InxMed (Shanghai) Co., Ltd.
InventisBio Co., Ltd

Recruiting

a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

Solid Tumor

China
Boehringer Ingelheim

Completed

A Study to Test How Well Different Doses of BI 1815368 Are Tolerated by Healthy Men

Healthy

Belgium
AbbVie

Completed

A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Psoriasis

Japan

3

Subscribe